Addressing the needs of individual patients remains at the forefront of Dr. West’s philosophy of care. The Mesothelioma.com editorial team works hard to offer current, factual, expert reviewed information about mesothelioma cancer and the risks of asbestos exposure. Editorial Guidelines | Disclaimer | Privacy Policy, 35 Thorpe Avenue, Suite 101 Saving You Time. 2018;378:2288-301. Medical Director of the Thoracic Oncology ProgramSwedish Cancer InstitutePresident & CEOGlobal Resource for Advancing Cancer Education (GRACE)Seattle, WA, 5900 N Andrews Avenue, Suite #500, Fort Lauderdale, FL 33309, Advancing the science of learning and behavior change in health care. Special management considerations for indolent lung cancers that may not require treatment or are at risk for “over-treatment.”. In the Teff-high population, progression-free survival was significantly longer in the ABCP group than in the BCP group (11.3 months vs. 6.8 months). PDL1 score 50% or greater: 20.0 months for pembrolizumab vs. 12.2 months for chemotherapy alone. Medical Director, Thoracic Oncology ProgramSwedish Cancer InstitutePresident & CEO, Global Resource for Advancing Cancer Education (GRACE)Seattle, Washington Dr. Jack West is a medical oncologist and Medical Director of the Thoracic Oncology Program at the Swedish Cancer Institute in Seattle, Washington. 1.800.336.0086. Watch Queue Queue. Copyright © 2018 Global Resource for Advancing Cancer EducationSite by Fuse IQ, Howard (Jack) West, MD, Associate Clinical Professor, Medical Oncology, Executive Director, Employer Services, Founder, President and CEO of GRACE, Dr. West received an M. Phil. Please confirm or complete the information below to complete registration. There was no statistically significant difference in progression-free survival. Host Dr. Jack West speaks with Sarah Mojarad, communications expert training scientists and medical students in how to integrate social media and build an online brand to extend the reach of their work while maintaining professionalism. PDL1 score 20% or greater: 17.7 months for pembrolizumab vs. 13.0 months for chemotherapy alone. Unclear if ABCP regimen is superior to pembrolizumab monotherapy (in greater than 50% PDL1 group) or pembrolizumab plus pemetrexed plus platinum agent (in all PDL1 groups) as a four-drug regimen may be less attractive than these options. Journal of Thoracic Oncology. Is the NCCN Undermining its Credibility by Failing to Acknowledge Bias and Value in its Guidelines? How Immunotherapy is Changing Practice Overall survival was longer in the ABCP group than in the BCP group (19.2 months vs. 14.7 months). Learn how immunotherapy is changing practice in lung cancer, from a presentation at the Seattle Science Foundation. See our Other Publications. Louis Jolyon "Jolly" West (October 6, 1924 – January 2, 1999) was an American psychiatrist whose work focused particularly on cases where subjects were "taken to the limits of human experience". Please fill in the form to request our FREE Mesothelioma Treatment Guide.It will be sent to you within 24 hours. MD West ONE has harnessed a network of the most advanced orthopedic, neurosurgery and spine care in the region. Use of this Web site is subject to the medical disclaimer. He also serves as President & CEO of the Global Resource for Advancing Cancer Education, a non-profit organization dedicated to providing current and clinically relevant information to cancer patients and the general public. The Plea for OpenTable for the clinic & research trials, Will AI have an algorithm for wishful thinking? October 2009;136(4):1112-1118. doi: 10.1378/chest.08-2484, Impact of the ASCO 2007 Presentation of HOG Lun 01-24 / USO-023 on the Prescribing Plans of American Medical Oncologists for Patients with Stage IIIB Non-small Cell Lung Cancer. Studies suggest blood type may impact the risk of SARS-CoV-2 infection, delays in screening could increase colorectal cancer deaths, and surgery is safe for most older women with ER+ breast cancer. H. Jack West, MD, joins the podcast to discuss the latest trials of immunotherapies in the treatment of lung cancer. Arnold Pavilion, Suite 200 Focusing on issues ranging from behavioral economics and decision … Sarah Mojarad: Social Media Training in Science and Medicine, Cancer Care in a Pandemic: Challenging the Status Quo, Dr. Christian Rolfo: Living and Working in 3 Continents, Now Working on Early Therapeutics, Liquid Biopsies, & Global Oncology, Marlene and Stewart Greenebaum Comprehensive Cancer Center. Swedish Cancer Institute at Swedish Medical Center, Complementary and Alternative Medicine in Cancer Care, Gemcitabine and pemetrexed administered in rapid sequence as front-line chemotherapy for advanced non-small-cell lung cancer: a phase II clinical trial, Histologic considerations for individualized systemic therapy approaches for the management of non-small cell lung cancer, Impact of the ASCO 2007 Presentation of HOG Lun 01-24 / USO-023 on the Prescribing Plans of American Medical Oncologists for Patients with Stage IIIB Non-small Cell Lung Cancer, Fellowship for Medical Oncology at University of Washington, Internship for Internal Medicine at Brigham and Women’s Hospital, Medical Degree from Harvard Medical School. Pembrolizumab monotherapy can be extended as first-line therapy to patients with locally advanced or metastatic non–small cell lung cancer and a high PDL1 score. Cancer Growth Rate and Managing Slow-Growing Lung Cancers N Engl J Med. Teff status has not yet been proven to be useful for clinical decision making. August 2009;4(8):983-987. doi: 10.1097/JTO.0b013e3181adeefb, Privacy policy: All information is secure and will never be released. GRACE - Global Resource for Advancing Cancer Education - 4616 25th Ave NE, # 300, Seattle, Washington 98105 - Rated 4.3 based on 15 Reviews "After a... 108 Followers, 115 Following, 53 Posts - See Instagram photos and videos from GRACE (@cancergrace). Overall survival is 16.7 months with pembrolizumab vs. 12.1 months with chemotherapy. Residents from Pennsylvania Hospital join Dr. David Henry to discuss the work-up and treatment of immune thrombocytopenia, how to diagnose and manage heparin-induced thrombocytopenia, and an "interesting" case of anemia. N Engl J Med. Wallingford, CT 06492. Jack West in Maryland. CHEST. Pembrolizumab monotherapy alone may not be the best choice for patients with a low PLD1 score. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non–small cell lung cancer (KEYNOTE-042): A randomised, open-label, controlled, phase 3 trial. Facebook gives people the power to share and makes the world more open and connected. He also serves as President of the medical education website OncTalk, LLC The professional website of Howard L. (Jack) West, MD - Thoracic Oncologist To discuss potential new programs or sponsorship/participation in current ones, please contact Dr. West. Much of Dr. West’s research focuses on pleural mesothelioma and other cancers of the lungs, and he has led numerous clinical trials in search of better treatment options for the disease. Dr. West maintains a strong clinical research focus on lung cancer and has authored dozens of peer-reviewed as well as invited publications. Beacon Medical Interchange is a venture founded in 2016 by Dr. Jack West to facilitate communication of medical experts with industry leaders on the evolution of medical care trends in general and cancer management in particular. Lancet. Dr. West is an associate clinical professor in medical oncology at City of Hope Comprehensive Cancer Center in Duarte, Calif., and a thought leader in thoracic oncology. Free Guide. Pembrolizumab plus chemotherapy in metastatic non–small cell lung cancer. Watch Queue Queue Mesothelioma.com is dedicated to providing the latest medical information on mesothelioma, spreading awareness about the dangers of asbestos exposure and providing victims with free resources. Atezolizumab plus bevacizumab plus carboplatin plus paclitaxel (ABCP) vs. bevacizumab plus carboplatin plus paclitaxel (BCP) vs. atezolizumab plus carboplatin plus paclitaxel (ACP), Patients with any PD-L1 immunohistochemistry status were eligible, Stratified by level of Teff gene-signature expression. In a continued effort to keep your information secure, we have upgraded our password security policy. Search. The information provided is for educational purposes only. 2018;378:2078-92. Help us make this podcast better! Prior results do not predict a similar outcome. Read more about H. Jack West, MD, Founder, President and CEO; ASCO Lung Cancer Roundtable - Trial Updates in NSCLC - ADAURA Trial and Post Surgery EGFR Mutation. https://www.surveymonkey.com/r/podcastsurveyOct2019, Hematology case review: ITP, HIT, and anemia, Choosing surgery for older breast cancer patients and more, TERAVOLT registry sheds light on patients with thoracic cancers and COVID-19, Would you choose oncology again? “My primary goal is to provide optimal balance of appropriate, aggressive treatment and a good quality of life,” he said. Video. Please take our short listener survey: https://www.surveymonkey.com/r/podcastsurveyOct2019, FDA Approves Ziextenzo for neutropenia-related infection reduction. He moved to City of Hope in March, 2019 to build programs to export subspecialty insights to patients across a broad geography. Dr. West is an associate clinical professor in medical oncology at City of Hope Comprehensive Cancer Center in Duarte, Calif., and a thought leader in thoracic oncology. The FDA has approved the biosimilar Ziextenzo to reduce the incidence of infection in patients with nonmyeloid cancer who are receiving suppressive anticancer drugs that are associated with febrile neutropenia. “This requires individualized plans based on a patient’s particular goals and medical issues.” For many patients, Dr. West explains, a treatment plan will include a chemotherapy combination of cisplatin and Alimta®, but there are alternatives for patients who can’t tolerate that regimen, such as the often better-tolerated carboplatin. Associate Clinical Professor, Medical Oncology, President & CEO, Global Resource for Advancing Cancer Education (GRACE). He performed a highly controversial psychiatric evaluation of Jack Ruby, and he was in charge of UCLA's department of psychiatry and the Neuropsychiatric Institute for 20 years. Dr. West received an M. Phil. Overall survival to 12 months: 69.2% with pembrolizumab plus chemotherapy vs. 49.4% with chemotherapy alone. He specializes in lung cancer. Progression-free survival: 8.8 months with pembrolizumab plus chemotherapy vs. 4.9 months with chemotherapy alone. My TEDx talk on how cancer patients and caregivers are becoming educated partners in their own care, fundamentally changing the dynamic of oncology. Please read our disclaimer for more information. Dr. Howard Jack West is a medical oncologist and medical director of the Thoracic Oncology Program at The Swedish Cancer Institute in Seattle, Washington and specializes in treating pleural mesothelioma. Progression-free survival was longer in the ABCP group than in the BCP group (8.3 months vs. 6.8 months). Human error as a valued feature in cancer care, 5 Key Algorithms for Artificial Intelligence to Improve on Human Limitations in Cancer Care, Vinod Khosla was right: Machine learning/algorithms can replace plenty of what physicians do. Dr. West is dedicated to improving cancer care and research. Howard (Jack) West, MD, is a medical oncologist and Medical Director of the Thoracic Oncology Program at the Swedish Cancer Institute in Seattle, WA. Howard Jack West is on Facebook. Unauthorized use prohibited. PDL1 score 1% or greater: 16.7 months for pembrolizumab vs. 12.1 months for chemotherapy alone. West, an associate clinical professor of medical oncology and executive director of Employer Services, made the move to build programs to export subspecialty … in Experimental Biology from Cambridge University on a Fulbright Scholarship before returning to the US to undertake his medical training at Harvard Medical School in Boston, where he earned his MD magna cum laude and conducted research as a Howard Hughes Medical Student Fellow.